Clinical trial · no report yet · Phase 2
A-DREAM
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
- NCT05241860 ↗
- Active not recruiting
- Alliance for Clinical Trials in Oncology
- 54 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 28 | |
| YouTube | 17 | |
| Podcasts | 8 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Castration-Sensitive Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8
- Interventions
- Pharmacotherapy Discontinuation; Follow-Up; Questionnaire Administration; Quality-of-Life Assessment
- Arms
- Treatment (discontinue hormonal medication, follow up) · Experimental
- Enrollment
- 79
- Primary outcomes
- Treatment-free With Eugonadal Testosterone (>= 150 ng/dl)
- Sponsor
- Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI)
- Start
- Nov 21, 2022
- Primary completion
- Sep 29, 2025
- Results posted
- Yes
- Registry record
- NCT05241860 · updated Sep 24, 2026